The Weekly Roundup: September 23-27

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Diversifying Psoriasis Research to Benefit the Population

Zelma Chiesa Fuxench, MD, MSCE, FAAD, and Mona Shahriari, MD, FAAD, discuss the lack of research into psoriasis in skin of color, the absence of diversity in clinical trial populations, and where dermatology as a discipline can go from here.

FDA Approves UCB's Bimekizumab-bkzx for Psoriatic Arthritis

Bimzelx was also approved for non-radiographic axial spondyloarthritis and ankylosing spondylitis.

Two Major Regulatory Milestones Announced for Delgocitinib for CHE

Announcements from both the FDA and the EC were supported by 2 clinical trials that evaluated the safety and efficacy of delgocitinib cream.

Skin Signs of Hereditary Angioedema

Review cutaneous signs and symptoms of HAE that may enhance early diagnosis and treatment.

How Managing Comorbidities Can Transform Alopecia Areata Treatment Outcomes

Understanding comorbidities such as thyroid dysfunction and vitiligo helps to navigate comprehensive care to achieve long-lasting results in alopecia areata treatment.

Considerations for Ancillary Services and Products in a Dermatology Practice

By offering a wide range of services, dermatologists can provide a holistic approach to skin health.

FDA Accepts Roflumilast Foam sNDA for Scalp and Body Psoriasis

The FDA has set a PDUFA target action date of May 22, 2025.

Top Insights from 5 Influential Leaders at Maui Derm NP+PA Fall

Learn more about the latest in dermatology from Sheila Fallon Friedlander, MD; Melodie Young, MSN, ANP-c; Raj Chovatiya, MD, PhD, MSCI; Julie Harper, MD; and Matthew Zirwas, MD.

NP & PA Conferences: 2024 in Review

As conference season approaches the last few months of the year, catch up on highlights from NP & PA conferences, including Fall Clinical for PAs and NPs and SDPA Summer.

Iain Stuart, PhD: VYN202 Positive Safety and Tolerability in Phase 1a

VYNE recently announced positive results for its novel oral small molecule BD2-selective BET inhibitor in a single-ascending dose clinical trial.

Aaron Farberg, MD: Image Guided SRT Achieves High Cure Rates in Non Melanoma Skin Cancer

Farberg discusses data recently published in Geriatrics demonstrating low rates of recurrence.

‘Next-Generation TYK2 Inhibitor’: Insights into Zasocitinib

Christopher Bunick, MD, PhD, shared insights into zasocitinib’s presented data and ongoing clinical trials.

AbbVie Presents New Data on Efficacy of Upadacitinib in Moderate to Severe Atopic Dermatitis, High-Impact Areas

A new analysis from phase 3 studies shows Rinvoq's effectiveness for moderate to severe AD with head and neck involvement.

Study Results Demonstrate High Secukinumab Persistence in Psoriasis Patient Population of Greece

Researchers presented interim 3-year results from the European SERENA study.

Study Reports Long-Term Efficacy of Lebrikizumab for AD

The study found that over 80% of patients who responded to lebrikizumab at week 16 maintained clear or almost-clear skin after 3 years.

Psoriasis within the US Hispanic Population: What Can Be Done to Diversify Clinical Data?

Mona Shahriari, MD, FAAD, shared insights into prevalence, clinical presentations, increasing research diversity, and advocating for representation.

Advancing Sexual Health Histories in Dermatology: A Modernized Comprehensive Approach for Diverse Populations

In recent years, there has been a noticeable rise in diagnoses of sexually transmitted infections, often which present with skin findings.

Semaglutide Demonstrates Potential, Improves Outcomes in Hidradenitis Suppurativa

In addition to decreases in BMI, researchers also reported fewer HS flare ups.

AI-Driven Chemistry: The Design Process Behind Zasocitinib

Through collaboration with Nimbus Therapeutics and Schrodinger, zasocitinib’s AI-driven design maximizes its fit within the targeted enzyme.

UCB Presents 4-Year Data on Bimekizumab for Plaque Psoriasis

The findings stem from post-hoc analyses of previous trials, which found that 75.1% of patients reached PASI100 after 1 year on bimekizumab.

Upadacitinib Demonstrates Efficacy in Patients With AD and Head and Neck Involvement

Kilian Eyerich, MD, PhD, shares insights into an EADV 2024 presentation on upadacitinib’s ability to achieve almost total skin clearance in the head and neck regions with minimal effect on quality of life.

Post Hoc Analysis of Vilobelimab in Hidradenitis Suppurativa Suggests Clinically Meaningful Benefits

Researchers reported reductions in draining tunnels and total lesion counts.

Positive Results Reported in Roflumilast 0.15% for AD Across Diverse Populations

“It is critical that our clinical data represent the diversity in the world around us, and these results further reinforce our commitment to providing meaningful innovation for immune-mediated skin diseases," said Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis.

Melinda Gooderham, MSc, MD, FRCPC: Insights Into Lebrikizumab’s Sustained 3-Year Efficacy

Gooderham reviews key highlights from EADV 2024 on the ADjoin long-term extension trial for patients with moderate to severe AD.

LEO Pharma Presents Extensive Data at EADV

Key highlights of the presentations included data on delgocitinib for atopic hand eczema, and tralokinumab for head and neck atopic dermatitis.

Deuruxolitinib Shows Efficacy in Hair Regrowth, Patient Satisfaction, and Psychosocial Wellbeing in Severe Alopecia Areata

Arash Mostaghimi, MD, MPH, MPA, provides insights into what clinicians need to know about deuruxolitinib for severe AA.